Our findings clarified the mode of action of this drug in the HSPC compartment, specifically Epag’s activity in promoting multilineage clonal expansion and thus its therapeutic efficacy in aplastic anemia. The gene discussed is DIAPH2-AS1; the disease is idiopathic aplastic anemia.